Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech announced cardiac safety data for Annamycin in R/R AML patients at the EHA Congress, showing no clinically significant cardiotoxicity across 90 subjects. The pooled analysis from five trials showed stable ejection fractions and no left ventricular dysfunction despite high cumulative anthracycline-equivalent doses. (Items: 7.01 Regulation FD Disclosure On May 12, 2026, Moleculin Biotech, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MBRX